1. Whitney, CG, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006; 368: 1495–1502.
2. Kellner, JD, et al. Progress in the prevention of pneumococcal infection. Canadian Medical Association Journal 2005; 173: 1149–1151.
3. Butler, JRG, et al. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 2004; 22: 1138–1149.
4. Pebody, RG, et al. Pneumococcal vaccination policy in Europe. Eurosurveillance 2005; 10: 174–178.
5. Lopalco, P (Editorial team). Use of 7-valent pneumococcal conjugate vaccine in EU. Eurosurveillance 2006; 11(12): E061207.3.
6. Grijalva, CG, et al. Decline in pneumonia admission after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007; 369: 1179–1186.
7. Dean, AG, et al. Epi-Info™: a general purpose microcomputer program for health information systems. American Journal of Preventive Medicine 1991; 7: 178–182.
8. Vergison, A, et al. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 2006; 118: 801–809.
9. Dagan, R, et al. Epidemiology of invasive childhood pneumococcal infections in Israel. Journal of the American Medical Association 1992; 268: 3328–3332.
10. Spanjaard, L, et al. Epidemiology of meningitis and bacteremia due to Streptococcus pneumoniae in The Netherlands. Acta Paediatrica (Suppl.) 2000; 89: 22–26.
11. Von Kries, R, et al. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clinical Infectious Diseases 2000; 31: 482–487.
12. Miller, E, et al. Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996–1998. Acta Paediatrica (Suppl.) 2000; 89: 11–16.
13. McIntosh, EDG, Fritzell, B, Fletcher, MA. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiology and Infection 2006; 7: 1–13.
14. Pebody, RG, et al. Pneumococcal disease surveillance in Europe. Eurosurveillance 2006; 11: 171–178.
15. Escola, J, et al. Epidemiology of invasive pneumococcal infections in children in Finland. Journal of the American Medical Association 1992; 268: 3323–3327.
16. Venetz, I, Schopfer, K, Muhlemann, K. Paediatric invasive pneumococcal disease in Switzerland, 1985–1994. International Journal of Epidemiology 1998; 27: 1101–1104.
17. Ispahani, P, et al. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation. Archives of Disease in Childhood 2004; 89: 757–762.
18. Kaltoft, MS, Zeuthen, N, Konradsen, HB. Epidemiology of invasive pneumococcal infections in children aged 0–6 years in Denmark: a 19-year nationwide surveillance study. Acta Paediatrica (Suppl.) 2000; 89: 3–10.
19. Hausdorff, WP. Invasive pneumococcal disease in children: geographic and temporal variations in incidence and serotype distribution. European Journal of Pediatrics 2002; 161: 135–139.
20. D'Ancona, F, et al. Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine 2005; 23: 2494–2500.
21. Hausdorff, WP, et al. Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use. Part 1. Clinical Infectious Diseases 2000; 30: 100–121.
22. Bossen Konradsen, H, Staum Kaltoft, M. Invasive pneumococcal infections in Denmark from 1995 to 1999: epidemiology, serotypes, and resistance. Clinical and Diagnostic Laboratory Immunology 2002; 9: 358–365.
23. O'Brien, KL, Dagan, R. The potential indirect effect of conjugate pneumococcal vaccines. Vaccine 2003; 21: 1815–1825.
24. Pedersen, MK, et al. Systemic pneumococcal disease in Norway 1995–2001: capsular types and antimicrobial resistance. Epidemiology and Infection 2004; 132: 167–175.
25. Serrano, I, et al. Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy. Clinical Microbiology and Infection 2004; 10: 652–656.
26. Von Kries, R, et al. Prediction of the potential benefit of different pneumococcal conjugate vaccines on invasive pneumococcal disease in German children. Pediatric Infectious Disease Journal 2002; 21: 1017–1023.
27. WHO position paper. Pneumococcal conjugate vaccine for childhood immunization. Weekly Epidemiological Record 2007; 82: 93–104.
28. Hammitt, LL, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. Journal of Infectious Diseases 2006; 193: 1487–1494.
29. Isaacman, DJ, et al. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine 2007; 25: 2420–2427.
30. Byington, CL, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the Intermountain West: emergence of nonvaccine serogroups. Clinical Infectious Diseases 2005; 41: 21–29.
31. Gonzalez, BE, et al. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatric Infectious Disease Journal 2006; 25: 301–305.